Oxaliplatin-sensitive cells respond trickly to the exosomal ciRS-122 from oxaliplatin-resistant cells, which endorses CRC glycolysis via enhancing PKM2 expression (152). This evidence concerns the gene PKM and colorectal carcinoma.